SG10201606618PA - Oral formulations and lipophilic salts of methylnaltrexone - Google Patents

Oral formulations and lipophilic salts of methylnaltrexone

Info

Publication number
SG10201606618PA
SG10201606618PA SG10201606618PA SG10201606618PA SG10201606618PA SG 10201606618P A SG10201606618P A SG 10201606618PA SG 10201606618P A SG10201606618P A SG 10201606618PA SG 10201606618P A SG10201606618P A SG 10201606618PA SG 10201606618P A SG10201606618P A SG 10201606618PA
Authority
SG
Singapore
Prior art keywords
methylnaltrexone
oral formulations
lipophilic salts
lipophilic
salts
Prior art date
Application number
SG10201606618PA
Other languages
English (en)
Inventor
Syed M Shah
Christopher Richard Diorio
Eric C Ehrnsperger
Xu Meng
Shareffi Kadum A Al
Jonathan Marc Cohen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201606618P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of SG10201606618PA publication Critical patent/SG10201606618PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201606618PA 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone SG10201606618PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
SG10201606618PA true SG10201606618PA (en) 2016-09-29

Family

ID=44148539

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2012057261A SG183133A1 (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone
SG10201501821RA SG10201501821RA (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone
SG10201606618PA SG10201606618PA (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG2012057261A SG183133A1 (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone
SG10201501821RA SG10201501821RA (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone

Country Status (32)

Country Link
US (8) US8524276B2 (zh)
EP (2) EP3178472B1 (zh)
JP (4) JP6143409B2 (zh)
KR (2) KR101913102B1 (zh)
CN (2) CN102918039B (zh)
AR (1) AR080491A1 (zh)
AU (1) AU2011224275B2 (zh)
BR (1) BR112012022873B1 (zh)
CA (1) CA2789798C (zh)
CL (1) CL2012002192A1 (zh)
CO (1) CO6630134A2 (zh)
CR (1) CR20120476A (zh)
EA (1) EA029096B1 (zh)
EC (1) ECSP12012208A (zh)
ES (1) ES2623926T3 (zh)
GE (1) GEP201606550B (zh)
GT (1) GT201200247A (zh)
HK (1) HK1245673A1 (zh)
HU (1) HUE033133T2 (zh)
IL (1) IL221452A (zh)
MA (1) MA34146B1 (zh)
MX (2) MX368805B (zh)
MY (1) MY160727A (zh)
NZ (3) NZ702826A (zh)
PE (1) PE20130063A1 (zh)
PL (2) PL3178472T3 (zh)
SG (3) SG183133A1 (zh)
TN (1) TN2012000392A1 (zh)
TW (2) TWI589293B (zh)
UA (2) UA123856C2 (zh)
WO (1) WO2011112816A1 (zh)
ZA (1) ZA201808498B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
ES2765811T5 (es) 2007-03-29 2024-02-27 Progenics Pharm Inc Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
WO2008153725A2 (en) 2007-05-25 2008-12-18 North Carolina State University Viral nanoparticle cell-targeted delivery platform
NZ702826A (en) 2010-03-11 2016-08-26 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
BR112014014805A2 (pt) * 2011-12-19 2017-06-13 Salix Pharmaceuticals Ltd processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
JP2017519803A (ja) * 2014-07-08 2017-07-20 インシス・ファーマ・インコーポレーテッド 舌下ナロキソンスプレー
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
CN113747882A (zh) * 2019-05-07 2021-12-03 博士医疗爱尔兰有限公司 甲基纳曲酮的液体口服剂量制剂
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
EP4142727A1 (en) 2020-05-02 2023-03-08 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
WO1998035679A1 (de) 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
ATE493130T1 (de) * 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CA2449175A1 (en) 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
AU2002360284B2 (en) 2001-10-18 2006-11-02 Nektar Therapeutics Polymer conjugates of opioid antagonists
ATE478065T1 (de) * 2001-11-29 2010-09-15 Schering Corp Verfahren zur herstellung von zusammensetzungen mit erhöhtem gehalt von salzen pharmazeutisch aktiver rotamere
CA2478558C (en) 2002-03-14 2012-09-11 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
US20050004155A1 (en) 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
WO2004091665A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
JP5165239B2 (ja) * 2003-07-15 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 制御放出処方物の調製のための方法
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
MXPA06007102A (es) 2003-12-19 2006-08-23 Schering Corp Composiciones farmaceuticas.
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
EP1809579B1 (en) 2004-09-30 2012-08-08 Becton, Dickinson and Company Method for reducing or eliminating residue in a glass medical container and container made in accordance therewith
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
CA2660100C (en) * 2006-08-16 2014-10-21 Novartis Ag Temporal photo-bleaching of colored lens care solutions and use thereof
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
PT2565195E (pt) * 2007-03-29 2015-07-28 Wyeth Llc Antagonistas e receptor opióide periférico e respectivas utilizações
ES2765811T5 (es) * 2007-03-29 2024-02-27 Progenics Pharm Inc Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
MX2010011727A (es) * 2008-05-07 2010-11-30 Nektar Therapeutics Administracion oral de antagonistas opioides que actuan perifericamente.
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
NZ702826A (en) 2010-03-11 2016-08-26 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
GEP201606550B (en) 2016-10-10
EP2371357A1 (en) 2011-10-05
CN102918039B (zh) 2017-06-09
EP3178472A1 (en) 2017-06-14
BR112012022873B1 (pt) 2021-09-14
PL2371357T3 (pl) 2017-09-29
US20190314365A1 (en) 2019-10-17
KR101913102B1 (ko) 2018-10-31
AR080491A1 (es) 2012-04-11
EA201270741A1 (ru) 2013-02-28
ES2623926T3 (es) 2017-07-12
MX349145B (es) 2017-07-14
NZ702826A (en) 2016-08-26
US20190117646A1 (en) 2019-04-25
HUE033133T2 (en) 2017-11-28
JP2011190259A (ja) 2011-09-29
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
CO6630134A2 (es) 2013-03-01
ECSP12012208A (es) 2015-03-31
US20120070495A1 (en) 2012-03-22
US20130330407A1 (en) 2013-12-12
CN102918039A (zh) 2013-02-06
MX368805B (es) 2019-10-17
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
CR20120476A (es) 2012-11-30
US8524276B2 (en) 2013-09-03
JP6429955B2 (ja) 2018-11-28
KR20130010900A (ko) 2013-01-29
NZ601595A (en) 2015-01-30
MX2012009125A (es) 2012-09-07
TW201622724A (zh) 2016-07-01
EP3178472B1 (en) 2021-10-27
JP6647368B2 (ja) 2020-02-14
JP2017206553A (ja) 2017-11-24
US9314461B2 (en) 2016-04-19
JP6143409B2 (ja) 2017-06-07
EP2371357B1 (en) 2017-02-01
US10376505B2 (en) 2019-08-13
CN107308125B (zh) 2021-07-16
US20190117645A1 (en) 2019-04-25
IL221452A (en) 2017-07-31
EA029096B1 (ru) 2018-02-28
GT201200247A (es) 2013-09-11
MA34146B1 (fr) 2013-04-03
WO2011112816A1 (en) 2011-09-15
IL221452A0 (en) 2012-10-31
US10307417B2 (en) 2019-06-04
US20160206612A1 (en) 2016-07-21
SG10201501821RA (en) 2015-05-28
PE20130063A1 (es) 2013-02-11
TWI589293B (zh) 2017-07-01
ZA201808498B (en) 2019-08-28
CN107308125A (zh) 2017-11-03
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
NZ703564A (en) 2016-08-26
US10507206B2 (en) 2019-12-17
US20140249171A1 (en) 2014-09-04
UA123856C2 (uk) 2021-06-16
JP2019034958A (ja) 2019-03-07
JP2016029054A (ja) 2016-03-03
SG183133A1 (en) 2012-09-27
HK1245673A1 (zh) 2018-08-31
MY160727A (en) 2017-03-15
BR112012022873A2 (pt) 2016-08-30
US20200121673A1 (en) 2020-04-23
CL2012002192A1 (es) 2012-09-28
TWI605814B (zh) 2017-11-21
AU2011224275A1 (en) 2012-08-23
CA2789798C (en) 2020-09-22
TW201141479A (en) 2011-12-01
UA111717C2 (uk) 2016-06-10
TN2012000392A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
ZA201808498B (en) Oral formulations and lipophilic salts of methylnaltrexone
EP2448406A4 (en) ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN WITH DELAYED RELEASE AND METHOD OF USE THEREOF
HK1183802A1 (zh) 治療性口腔組合物
IL222919A0 (en) Alcohol - resistant oral pharmaceutical form
EP2461691A4 (en) THERAPEUTIC VITAMIN D SUNSCREEN FORMULATIONS AND METHOD OF USE THEREOF
EP2548859A4 (en) PREPARATION OF METHYL-D3-AMINE AND SALTS THEREOF
HK1183228A1 (zh) 口服藥物治療方法和組合物
ZA201205441B (en) Dental strip for administration of oral treatment
ZA201300160B (en) Formulations including amiodarone and salts thereof and methods of their manufacture and use
EP2714024A4 (en) ORAL FORMULATIONS FROM ANTIOXIDANTS FACED ON MITOCHONDRIA AND THE PREPARATION AND USE THEREOF
IL223311A0 (en) Oral dosage forms of bendamustine
HUE053412T2 (hu) Loratadin gyógyászati kiszerelései kapszulába záráshoz, és ezek kombinációi
IL224191A (en) Compositions of vitamin d and cmc epi-14 analogues
ZA201207945B (en) Salts of dexlansoprazole and their preparation
EP2780029A4 (en) ORAL LEPTIN FORMULATIONS AND USES THEREOF
SI2654723T1 (sl) Trdne farmacevtske dozirna oblike, ki obsegajo tadalafil in metode za njihovo pripravo
EP2419085A4 (en) IMPROVED DEVICES FOR ORAL MEDICINAL PRODUCTS AND MEDICINAL PRODUCTS
EP2529755A4 (en) PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION
TWM390131U (en) Improved structure of dental scaler
GB201018760D0 (en) An oral dosage form
GB0906003D0 (en) Oral drug formulation
PL390434A1 (pl) Preparat leczniczy
TWM388322U (en) Improved structure of dental handpiece
GB201012046D0 (en) Pharmaceutical formulations
GB201012047D0 (en) Pharmaceutical formulations